Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology, using engineered proteins and live biotherapeutic products. Azitra has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts, and helps screen our library of strains for drug like molecules. Azitra's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis. Azitra's lead program is ATR-12, which is a genetically engineered strain of S. epidermidis which secretes the recombinant protein, LEKTI. ATR-12 is currently in a Phase 1b clinical trial for Netherton syndrome, a rare skin disease caused by missing LEKTI protein.